209 related articles for article (PubMed ID: 23541883)
21. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
Gurunathan S; Prussin C; Sacks DL; Seder RA
Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
[TBL] [Abstract][Full Text] [Related]
22. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen.
Badiee A; Khamesipour A; Samiei A; Soroush D; Shargh VH; Kheiri MT; Barkhordari F; Robert Mc Master W; Mahboudi F; Jaafari MR
Exp Parasitol; 2012 Dec; 132(4):403-9. PubMed ID: 22982807
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of immune responses induced by SAG1 and MIC3 vaccine cocktails against Toxoplasma gondii.
Fang R; Feng H; Hu M; Khan MK; Wang L; Zhou Y; Zhao J
Vet Parasitol; 2012 Jun; 187(1-2):140-6. PubMed ID: 22336771
[TBL] [Abstract][Full Text] [Related]
24. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
25. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
26. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
27. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
28. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
29. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.
Mortazavidehkordi N; Fallah A; Abdollahi A; Kia V; Khanahmad H; Najafabadi ZG; Hashemi N; Estiri B; Roudbari Z; Najafi A; Farjadfar A; Hejazi SH
Parasitol Res; 2018 Jul; 117(7):2265-2273. PubMed ID: 29845415
[TBL] [Abstract][Full Text] [Related]
30. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
31. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.
Tafaghodi M; Eskandari M; Khamesipour A; Jaafari MR
Exp Parasitol; 2011 Oct; 129(2):107-14. PubMed ID: 21767536
[TBL] [Abstract][Full Text] [Related]
32. Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant.
Zhou H; Min J; Zhao Q; Gu Q; Cong H; Li Y; He S
Vaccine; 2012 Feb; 30(10):1800-6. PubMed ID: 22240340
[TBL] [Abstract][Full Text] [Related]
33. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.
Bolhassani A; Gholami E; Zahedifard F; Moradin N; Parsi P; Doustdari F; Seyed N; Papadopoulou B; Rafati S
Exp Parasitol; 2011 May; 128(1):9-17. PubMed ID: 21276444
[TBL] [Abstract][Full Text] [Related]
34. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Li J; Nolan TJ; Farrell JP
Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii.
Xue M; He S; Cui Y; Yao Y; Wang H
Parasitol Int; 2008 Dec; 57(4):424-9. PubMed ID: 18562245
[TBL] [Abstract][Full Text] [Related]
36. Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model.
Fang R; Feng H; Nie H; Wang L; Tu P; Song Q; Zhou Y; Zhao J
Vaccine; 2010 Feb; 28(7):1803-7. PubMed ID: 20018269
[TBL] [Abstract][Full Text] [Related]
37. [Immunogenicity of the recombinant plasmid of Leishmania donovani amastigote gene].
Li JF; Chen JP; Tian Y; Yang ZW; Ma Y; Hu XS
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2011 Apr; 29(2):122-5. PubMed ID: 21826897
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of DNA-mediated immunization with a combination of SAG1 and IL-2 gene adjuvant against infection of Toxoplasma gondii in mice.
Chen G; Chen H; Guo H; Zheng H
Chin Med J (Engl); 2002 Oct; 115(10):1448-52. PubMed ID: 12490084
[TBL] [Abstract][Full Text] [Related]
39. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
